Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis

A Bahji, D Ermacora, C Stephenson… - Journal of affective …, 2020‏ - Elsevier
Objective We investigated the comparative efficacy and tolerability of pharmacological
treatment strategies for the treatment of acute bipolar depression. Data sources A systematic …

Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies

CT Li, KC Yang, WC Lin - Frontiers in psychiatry, 2019‏ - frontiersin.org
Excessive glutamate release has been linked to stress and many neurodegenerative
diseases. Evidence indicates abnormalities of glutamatergic neurotransmission or …

Glutamatergic neurotransmission: pathway to develo** novel rapid-acting antidepressant treatments

B Kadriu, L Musazzi, ID Henter, M Graves… - International Journal …, 2019‏ - academic.oup.com
The underlying neurobiological basis of major depressive disorder remains elusive due to
the severity, complexity, and heterogeneity of the disorder. While the traditional …

A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA …

ST Wilkinson, G Sanacora - Drug discovery today, 2019‏ - Elsevier
Highlights•Monoamine deficiency hypothesis cannot explain the neurobiology of mood
disorders.•Amino acid neurotransmitters are central to the pathophysiology of mood …

High-fat diet induces depression-like phenotype via astrocyte-mediated hyperactivation of ventral hippocampal glutamatergic afferents to the nucleus accumbens

SF Tsai, PL Hsu, YW Chen, MS Hossain, PC Chen… - Molecular …, 2022‏ - nature.com
Comorbidity exists between metabolic disorders and depressive syndrome with unclear
mechanisms. To characterize the causal relationship, we adopted a 12-week high-fat diet …

The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder

R Guglielmo, G Hasler - Neuroscience & Biobehavioral Reviews, 2022‏ - Elsevier
The monoamine hypothesis has dominated research on the pathophysiology of mood
disorders as well as the development of therapeutic drugs by over half a century. Nowadays …

Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool

V Lazarevic, Y Yang, D Ivanova, A Fejtova… - …, 2018‏ - Elsevier
Riluzole is a potent neuroprotective agent which primarily inhibits excitatory
neurotransmission interfering with presynaptic release, uptake and postsynaptic actions of …

Riluzole regulates pancreatic cancer cell metabolism by suppressing the Wnt-β-catenin pathway

SK Roy, Y Ma, BQ Lam, A Shrivastava, S Srivastav… - Scientific Reports, 2022‏ - nature.com
Most cancer cells rely on aerobic glycolysis to support uncontrolled proliferation and evade
apoptosis. However, pancreatic cancer cells switch to glutamine metabolism to survive …

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder

RL Dean, T Marquardt, C Hurducas… - Cochrane Database …, 2021‏ - cochranelibrary.com
Background Glutamergic system dysfunction has been implicated in the pathophysiology of
bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate …

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

W Guo, R Machado-Vieira, S Mathew… - Translational …, 2018‏ - nature.com
Growing evidence suggests that the glutamatergic modulator ketamine has rapid
antidepressant effects in treatment-resistant depressed subjects. The anticholinergic agent …